Calley Means on ozempic: what the evidence says · JRE #2210
SUBJECT: OZEMPIC
Not a true/false call. Every claim is logged with its sources; read the exhibits below.
So the second this bill is signed, $1,600 per patient per month, taxpayer money, which is why Novonortix is the ninth most valuable company in the world right now, this Danish company expecting 90% of their profits from the United States on expectation of this bill's passage.
What the evidence says 01 / RECORD
The underlying direction is real (the U.S. is by far Novo Nordisk's most important market and its GLP-1 drugs carry very high U.S. list prices), but the specific figures are wrong or inflated. At its March 2024 peak Novo Nordisk was the 12th most valuable company in the world, at about $604 billion, not the ninth, and it was never ranked ninth globally; it was Europe's most valuable company and the second-largest drugmaker behind Eli Lilly. The $1,600 per patient per month figure is above actual U.S. list prices: the highest-priced GLP-1, Wegovy, lists at roughly $1,349 per month, and U.S. prices, while far higher than in peer nations, do not reach $1,600. CMS and CBO estimates put the Medicare cost of expanding anti-obesity coverage at roughly $24.8 to $35.5 billion over about a decade rather than any single per-patient figure like the one cited. The 90 percent of profits from the U.S. claim overstates U.S. dependence: North America Operations is roughly half of Novo Nordisk's sales, not 90 percent.